Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VGX Pharmaceuticals' novel pandemic influenza vaccine candidates triggered protective immune responses in preclinical challenge studies, according to data presented at the Third International Conference on DNA Vaccines in Malaga, Spain.
Subscribe to our email newsletter
VGX scientists created four synthetic consensus DNA vaccines to protect against a lethal Vietnamese H5N1strain of avian influenza in mice. One of the vaccines resulted in complete protection of mice from death and illness of the challenge while 2 others had 60-80% protective effects. All of the vaccines were delivered using VGX’s proprietary CELLECTRA DNA Delivery Device. CELLECTRA is a novel adaptive electroporation device developed by VGX. The avian flu data was presented by Dr Ruxandra Draghia-Akli, VGX vice president, Immune Therapeutics Research.
Separately at the opening plenary session, professor David Weiner of the University of Pennsylvania, conference chairman and a co-founder of VGX, presented new data showing extensive T-cell mediated immune responses to VGX’s HIV vaccine candidates delivered with CELLECTRA in non-human primates.
The data revealed that the monkeys immunized with VGX vaccines displayed HIV-specific T cell responses as much as 10-20 fold greater than those reported in the literature using other vaccine modalities.
VGX plans to conduct further preclinical studies for both the HIV and Avian Flu vaccines, including the IND-enabling toxicology studies in 2007.